Prior studies report differing sensitivities to HIF-2α inhibitors in ccRCC lines, and we considered whether an interaction with CBF-β and HIF-2α could explain the varied sensitivity of ccRCC lines to impaired growth with CBFB loss39. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.